Excess Mortality Associated with Colistin-Tigecycline Compared with Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study

Critical Care Medicine

Volumn 43, Issue 6, 2015, Pages 1194-1204

  Cheng, Aristine ^a   Chuang, Yu Chung ^b   Sun, Hsin Yun ^a   Sheng, Wang Huei ^a   Yang, Chia Jui ^c   Liao, Chun Hsing ^c   Hsueh, Po Ren ^a   Yang, Jia Ling ^a   Shen, Ni Jiin ^a   Wang, Jann Tay ^a   Hung, Chien Ching ^a   Chen, Yee Chun ^a   Chang, Shan Chwen ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acinetobacter baumannii; carbapenem combination therapy; colistin; extensively drug resistant; tigecycline

Indexed keywords

CARBAPENEM; COLISTIN; TIGECYCLINE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ACINETOBACTER INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; CONCENTRATION AT STEADY-STATE; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY; NONHUMAN; OBSERVATIONAL STUDY; PRIMARY INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; TAIWAN; ACINETOBACTER INFECTIONS; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; INTENSIVE CARE UNIT; KAPLAN MEIER METHOD; MALE; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MULTIDRUG RESISTANCE; ORGAN DYSFUNCTION SCORE;

ACINETOBACTER INFECTIONS; ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTENSIVE CARE UNITS; KAPLAN-MEIER ESTIMATE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; ORGAN DYSFUNCTION SCORES; PROSPECTIVE STUDIES; TAIWAN;

EID: 84937578574     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000933     Document Type: Article

References (65)

1. Kuo SC, Chang SC, Wang HY, et al; TSAR Hospitals: Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: Nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect Dis 2012; 12:200
2. Su CH, Wang JT, Hsiung CA, et al: Increase of carbapenem-resistant Acinetobacter baumannii infection in acute care hospitals in Taiwan: Association with hospital antimicrobial usage. PLoS One 2012; 7:e37788
3. Perez F, Hujer AM, Hujer KM, et al: Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:3471-3484
4. Maragakis LL, Perl TM: Acinetobacter baumannii: Epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008; 46:1254-1263
5. Sengstock DM, Thyagarajan R, Apalara J, et al: Multidrug-resistant Acinetobacter baumannii: An emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 2010; 50:1611-1616
6. Jean SS, Hsueh PR, Lee WS, et al: Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009; 33:266-271
7. Magiorakos AP, Srinivasan A, Carey RB, et al: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard defnitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-281
8. Poulikakos P, Tansarli GS, Falagas ME: Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: A systematic review. Eur J Clin Microbiol Infect Dis 2014; 33:1675-1685
9. Spellberg B, Bonomo RA: The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med 2014; 42:1289-1291
10. Lee HY, Chen CL, Wu SR, et al: Risk factors and outcome analysis of Acinetobacter baumannii complex bacteremia in critical patients. Crit Care Med 2014; 42:1081-1088
11. Chuang YC, Chang SC, Wang WK: Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia. Crit Care Med 2012; 40:2273-2280
12. Sheng WH, Wang JT, Li SY, et al: Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011; 70:380-386
13. Tan CH, Li J, Nation RL: Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2007; 51:3413-3415
14. Li J, Nation RL, Owen RJ, et al: Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: Promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007; 45:594-598
15. Li J, Rayner CR, Nation RL, et al: Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50:2946-2950
16. Hawley JS, Murray CK, Jorgensen JH: Colistin heteroresistance in acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008; 52:351-352
17. Pogue JM, Lee J, Marchaim D, et al: Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-884
18. Deryke CA, Crawford AJ, Uddin N, et al: Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54:4503-4505
19. Falagas ME, Rizos M, Bliziotis IA, et al: Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5:1
20. Ye JJ, Lin HS, Kuo AJ, et al: The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 2011; 63: 351-361
21. Shields RK, Clancy CJ, Gillis LM, et al: Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 2012; 7:e52349
22. Hernández-Torres A, García-Vázquez E, Gómez J, et al: Multidrug and carbapenem-resistant Acinetobacter baumannii infections: Factors associated with mortality. Med Clin (Barc) 2012; 138:650-655
23. Prasad P, Sun J, Danner RL, et al: Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699-1709
24. Chuang YC, Cheng CY, Sheng WH, et al: Effectiveness of tigecy-cline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: A matched cohort analysis. BMC Infect Dis 2014; 14:102
25. Yahav D, Lador A, Paul M, et al: Effcacy and safety of tigecycline: A systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1963-1971
26. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39:165-228
27. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416
28. Petrosillo N, Ioannidou E, Falagas ME: Colistin monotherapy vs. combination therapy: Evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008; 14:816-827
29. Sirijatuphat R, Thamlikitkul V: Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014; 58:5598-5601
30. Zusman O. In Vitro synergy of polymixins and carbapenems: Systematic review and meta analysis. Antimicrob Agents Chemother 2013; 57: 5104-5111.
31. Dizbay M, Tozlu DK, Cirak MY, et al: In vitro synergistic activity of tigecycline and colistin against XD R-Acinetobacter baumannii. J Antibiot (Tokyo) 2010; 63:51-53
32. Ni W, Cui J, Liang B, et al: In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii. J Antibiot (Tokyo) 2013; 66:705-708
33. Lin YC, Sheng WH, Chen YC, et al: Differences in carbapenem resistance genes among Acinetobacterbaumannii, Acinetobacter genospecies 3 and Acinetobacter genospecies 13TU in Taiwan. Int J Antimicrob Agents 2010; 35:439-443
34. Chuang YC, Sheng WH, Li SY, et al: Influence of genospecies of Acinetobacter baumannii complex on clinical outcomes of patients with acinetobacter bacteremia. Clin Infect Dis 2011; 52:352-360
35. Tan CK, Liu WL, Lai CC: Different genospecies of Acinetobacter cal-coaceticus-Acinetobacter baumannii complex associated with different outcomes. J Crit Care 2011; 26:525-526
36. Park KH, Shin JH, Lee SY, et al: The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies. PLoS One 2014; 8:e65026
37. Chiang MC, Kuo SC, Chen SJ, et al: Clinical characteristics and outcomes of bacteremia due to different genomic species of Acinetobacter baumannii complex in patients with solid tumors. Infection 2012; 40:19-26
38. Karageorgopoulos DE, Falagas ME: Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008; 8:751-762
39. López-Cortés LE, Rodríguez Baño J: Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: Analysis of a multicentre prospective cohort-authors' response. J Antimicrob Chemother 2014; 69:3167-3168
40. Batirel A, Balkan II, Karabay O, et al: Comparison of colistin-carbape-nem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33:1311-1322
41. Ku K, Pogue JM, Moshos J, et al: Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control 2012; 40:983-987
42. Oliveira MS, Prado GV, Costa SF, et al: Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61:1369-1375
43. Lee YT, Kuo SC, Yang SP, et al: Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: Relation to severity of infection. Clin Infect Dis 2012; 55:209-215
44. Webster NR. Professors live longer than doctors: Immortality bias in survival analysis. British Journal of Anaesthesia 2011; 106: 161-163.
45. Lee YC, Huang YT, Tan CK, et al: Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: Comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011; 66:1839-1846
46. Tien N, You BJ, Chang HL, et al: Comparison of genospecies and antimicrobial resistance profiles of isolates in the Acinetobacter calcoaceticus-Acinetobacter baumannii complex from various clinical specimens. Antimicrob Agents Chemother 2012; 56:6267-6271
47. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing: 17th Informational Supplement, M100-S17. Wayne, PA. CLSI, 2007
48. Comite de lAntibiogramme de la Societe Francaise de Microbiologie: Recommandations 2012. Paris, France, CA-SFM, 2012
49. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373-383
50. Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance defnition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-332
51. Garonzik SM, Li J, Thamlikitkul V, et al: Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-3294
52. Gauthier TP, Wolowich WR, Reddy A, et al: Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56:2392-2396
53. Noskin GA: Tigecycline: A new glycylcycline for treatment of serious infections. Clin Infect Dis 2005; 41(Suppl 5):S303-S314
54. Stein GE, Craig WA: Tigecycline: A critical analysis. Clin Infect Dis 2006; 43:518-524
55. Gardiner D, Dukart G, Cooper A, et al: Safety and effcacy of intravenous tigecycline in subjects with secondary bacteremia: Pooled results from 8 phase III clinical trials. Clin Infect Dis 2010; 50:229-238
56. Anthony KB, Fishman NO, Linkin DR, et al: Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567-570
57. Navon-Venezia S, Leavitt A, Carmeli Y: High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59:772-774
58. Cai Y, Chai D, Wang R, et al: Colistin resistance of Acinetobacter baumannii: Clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012; 67:1607-1615
59. Papp-Wallace KM, Endimiani A, Taracila MA, et al: Carbapenems: Past, present, and future. Antimicrob Agents Chemother 2011; 55:4943-4960
60. Falagas ME, Vardakas KZ, Tsiveriotis KP, et al: Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents 2014; 44:1-7
61. Cho SY, Kang CI, Chung DR, et al: Breakthrough bacteremia due to extended-spectrum-lactamase-producing Klebsiella pneumoniae during combination therapy with colistin and tigecycline. Antimicrob Agents Chemother 2012; 56:4994-4995; author reply 4996
62. Falagas ME, Rafailidis PI, Matthaiou DK, et al: Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 2008; 32:450-454
63. Munoz-Price LS, Fajardo-Aquino Y, Arheart KL, et al: Aerosolization of Acinetobacter baumannii in a trauma ICU∗. Crit Care Med 2013; 41:1915-1918
64. Spellberg B, Bonomo RA: "Airborne assault": A new dimension in Acinetobacter baumannii transmission∗. Crit Care Med 2013; 41:2042-2044
65. Huang DB, Pastagia M, Chiang T: Challenges to conducting a clinical trial of combination therapy of colistin and rifampicin for extensively drug-resistant Acinetobacter baumannii. Clin Infect Dis 2014; 58:141-142